leisure time -WSS

leisure time

author：explore 2025-10-01 23:38:49 - browse：561

Ula Jurkunas, associate director of the cornea service at Mass Eye and Ear, performs the first CALEC surgery. Courtesy Mass Eye and Ear

The first time Phillip Durst saw the big A on the chart, he could hardly believe it. It was the first in a series of letters to check his vision in his left eye. “They keep flipping the chart and it keeps getting smaller and smaller, and I keep identifying the letters — that was huge,” said Durst. “It’s like a miracle.”

A year earlier, in April 2017, Durst had lost sight from that same eye after it was hit by a caustic water treatment solution in a work accident. The damage was so severe that a standard corneal transplant would not resolve it. But in April 2018, he underwent a new, innovative procedure: An eye stem cell transplant led by Ula Jurkunas, the associate director of the cornea service at Mass Eye and Ear in Boston.

Durst, now 51 years old, is the first of four patients who were included in a Phase 1 trial of Cultivated Autologous Limbal Epithelial Cell (CALEC) transplant, the results of which were published Friday in Science Advances. The procedure allowed him to become a suitable candidate for another surgery, the artificial corneal transplant, while rehabilitating his vision — and his life.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Radiology is caught between AI's potential and concern for patients

hotspot

leisure time

WSS

Positive childhood experiences can help future health

What PEPFAR has meant on the ground in Ukraine

UnitedHealth increases loan offers after Change Healthcare outage

Orchard's therapy for neuron disease in children wins FDA approval

What PEPFAR has meant on the ground in Ukraine

Positive childhood experiences can help future health

knowledge

leisure time

focus

Hollywood unions extend contract negotiations for actors

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

Psychedelics group wrestles with new pharma identity

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

Supreme Court strikes down use of affirmative action

AstraZeneca to buy developer of next

New air purifier tech could be key to improving indoor air quality

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Novavax promises a turnaround & Lilly roils the obesity market

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

explore

Creating egg and sperm cells from stem cells raises ethical issues

Baby aspirin cuts fat buildup in liver disease patients, in small study

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

What PEPFAR has meant on the ground in Ukraine

Orchard's therapy for neuron disease in children wins FDA approval

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

focus

hotspot

leisure time

leisure time